Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17080255 | 0.87 | KDM4E (0.48) | CYP1A2CYP2C9ALDH1A1KDM4EHTT | |
| SCHEMBL12553299 | 0.84 | CHEK1 (0.44) | CYP1A2CYP2C9ALDH1A1KDM4EEPAS1 | |
| SCHEMBL1811627 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EHTTEPAS1SMN1; SMN2 | |
| SCHEMBL3339856 | 0.81 | HPGD (0.51) | ALDH1A1KDM4EHTTEPAS1SMN1; SMN2 | |
| SCHEMBL4634707 | 0.80 | EPAS1 (0.47) | ALDH1A1KDM4EEPAS1SMN1; SMN2L3MBTL1 | |
| SCHEMBL5937228 | 0.80 | CYP46A1 (0.43) | TDP1ALDH1A1KDM4EHTTEPAS1 | |
| SCHEMBL2314446 | 0.80 | NOTUM (0.47) | CYP2C9ALDH1A1KDM4EEPAS1SMN1; SMN2 | |
| SCHEMBL7654198 | 0.79 | RAB9A (0.44) | ALDH1A1KDM4EHTTEPAS1SMN1; SMN2 | |
| SCHEMBL15826901 | 0.79 | EPAS1 (0.49) | CYP1A2CYP2C9ALDH1A1KDM4EHTT | |
| SCHEMBL974920 | 0.79 | HSD11B1 (0.45) | CYP1A2CYP2C9TDP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | KAT6A 1485/4885CYP1A2 115/4885CYP2C9 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.